Business Context and Reporting Period
This Form 8-K, dated July 23, 2019, reports on KBL Merger Corp. IV (KBL), a Special Purpose Acquisition Company (SPAC) listed on NASDAQ. The filing details the entry into a Business Combination Agreement on July 25, 2019, with CannBioRx Life Sciences Corp. and its subsidiaries. The transaction involves a merger where KBL will acquire 100% of the target company's equity in exchange for KBL common stock.
Key Financial Metrics and Transaction Terms
- Transaction Valuation: The equity consideration is valued at $175 million, based on a share price of $10.00 per Transaction Share.
- Liability Adjustment: The $175 million consideration is subject to reduction by any liabilities of the target company exceeding $5 million at closing.
- Backstop Financing: Tyche Capital LLC has agreed to purchase shares to ensure KBL maintains at least $5,000,001 in net tangible assets post-closing.
- Contemplated Financing: The parties intend to seek approximately $50 million in additional financing for research and development and working capital.
- Executive Compensation:
- Marlene Krauss (CEO): $500,000 base salary, 50% target bonus, and 3.75% equity award of fully-diluted shares.
- George Hornig (COO/Acting CFO): $250,000 base salary, 50% target bonus, and an equity award amount to be determined by the Board.
Material Changes and Transaction Structure
The filing represents a material change in KBL's corporate structure and business focus, transitioning from a shell company to an operating entity in the life sciences sector. Key structural elements include:
- Board Composition: The post-merger board will consist of eight directors: two designated by KBL, three by the Company, and three mutually agreed upon.
- Support and Lock-Up: Approximately 52% of the target company's stockholders have signed support agreements to vote in favor. Approximately 90% of stockholders have agreed to lock-up restrictions for one year or until the stock price exceeds $12.00 for 20 trading days within a 30-day period (150 days post-merger).
- Escrow: 6% of Transaction Shares will be held in escrow to satisfy indemnification obligations for 12 months post-closing.
Guidance, Risks, and Contingencies
The transaction is subject to several closing conditions, including stockholder approval from both KBL and the target company, regulatory approvals, and the effectiveness of a registration statement. The filing includes extensive forward-looking statements regarding the timing of the merger, the ability to meet Nasdaq listing standards, and the target company's ability to develop drug products.
Key Risks Identified:
- Failure to obtain required stockholder or regulatory approvals.
- Inability to secure the contemplated $50 million financing.
- Redemptions by KBL stockholders reducing available cash.
- Development risks associated with the target company's drug products and intellectual property.
Investor Verification Checklist
- Verify the final valuation and liability adjustments in the definitive proxy statement/prospectus (Form S-4).
- Confirm the status of the $50 million contemplated financing and the terms of the Tyche Capital backstop agreement.
- Review the target company's financial statements and R&D pipeline details in the upcoming proxy materials.
- Monitor the outcome of the stockholder vote required to approve the business combination.
- Assess the impact of the 6% escrow holdback on immediate liquidity and share availability.